MacroGenics, Merck Seize Gastric Cancer Opportunity With Margetuximab, Keytruda Combo
This article was originally published in Scrip
MacroGenics Inc. will study the ability of margetuximab to enhance the immune system's destruction of HER2-positive tumors in a Phase Ib/II clinical trial to evaluate the monoclonal antibody in combination with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) in advanced gastric cancer.
You may also be interested in...
MacroGenics' BLA for full approval in the US is under way and the company already has established a manufacturing facility in preparation for a launch.
Janssen Biotech Inc. apparently likes what it's seen so far from the first bi-specific antibody that it licensed from MacroGenics Inc., because the Johnson & Johnson subsidiary obtained rights to a second asset from the Rockville, Maryland-based firm's Dual Affinity Re-Targeting (DART) platform.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.